the invention relates to a pharmaceutical composition, hereinafter pharmaceutical composition of the invention, comprising fingolimod, an analogue, metabolite or derivative thereof or a pharmaceutically acceptable salt, and one or more drugs selected from the group consisting of an antioxidant, an antioxidant targeted to mitochondria, a histone deacetylase inhibitor, an inhibitor of mitochondria transition pore opening, an anti-inflammatory drug, a PPAR agonist, a RXR agonist, a sirtuin 1 agonist, an hypolipidemic drug and an autophagy activator
Regulation of mitochondrial homeostasis by mTORC1 and mTORC2 Both mTORC1 and mTORC2 are essential for mitochondrial biogenesis, dynamics, the phosphorylation of mitochondrial proteins, mitochondrial genome repair, the cellular response to mitochondrial ROS, and the regulation of mitophagy
.Gcel provides a blend of herbalomic ingredients along with acetyl-glutathione designed to help boost the bodys production of glutathione peroxidase, a primary antioxidant throughout the entire body
Research by GPS has the potential to enhance the expression of pro-apoptotic proteins, including Bax, which is a critical metabolite of the Bcl-2 protein family